--- title: "Rules First: China's Case for Regulating AI While It Is Still Being Built" date: 2026-08-28 category: Policy & Governance site: NeuroAI canonical: https://neuroai.site/a/na-governance-and-standards language: en --- # Rules First: China's Case for Regulating AI While It Is Still Being Built > From brain-interface ethics to generative content labelling, China has shipped a dense body of AI rules. Whatever one thinks of the approach, the rulebook exists — and now it is being exported as standards. The Western debate about AI governance is largely prospective: what rules should we write? China's is largely retrospective, because many rules are already written and being revised. This is the least covered and arguably most consequential difference between the two systems. ## Key takeaways - **Governance is now a top-level economic priority**, not just a safety one: the July 2026 Politburo meeting paired "deep implementation of the AI+ action" with "improving the AI governance system" in the same sentence. - **Brain-computer interfaces are a regulated medical field** with dedicated ethical guidance and technical standards, an unusual level of specificity for a technology most countries have not yet legislated. - **Generative AI is regulated by output**: labelling requirements, training-data provenance expectations and registration obligations apply to services offered to the public. - **Standards are the export vector**: China has pushed its technical standards work through international bodies, particularly in areas where it leads deployment — industrial AI, smart manufacturing, and neurotechnology. - **The WHO framing shift**: at the 79th World Health Assembly, international consensus formed around AI-era health governance moving from "how to treat illness" toward "how to keep health happening." ## What a written rulebook does The pragmatic argument for early regulation is that it converts an argument about principles into a compliance checklist. A hospital considering a brain-interface trial, or a company shipping a video generator, needs to know what is permitted before investing — not after. This matters most in the areas where China has genuine clinical and industrial volume. When the first Chinese BCI trials moved from single cases to dozens of implanted patients, the ethical questions — informed consent for participants who cannot speak, data ownership for neural signals, long-term device support — stopped being hypothetical. Having a published position on them is what allows multi-centre trials to recruit at all. The same logic applies to generative media. Kling's 100 million users and nearly 50,000 enterprise customers exist inside a system where labelling and provenance obligations are defined. That is a constraint on the product, and also the reason enterprise customers in regulated industries are willing to use it. ## The legitimate criticisms Three objections deserve to be taken seriously rather than waved away: **Compliance cost favours incumbents.** Registration, review and data obligations are easier for a company with a legal department than for a three-person startup. Any regulatory regime has this effect; the question is whether the threshold is calibrated. **Vagueness creates caution.** Rules that require content to reflect "core values" without operational definitions leave platforms to over-moderate. This is a well-documented dynamic and it shapes what gets built. **Standards as industrial policy.** When a country leads deployment in a category and then writes the international standard for it, the standard inevitably reflects its architecture. This is true of every standards-setting process in history, and it is a reasonable source of unease for competitors. None of these are unique to China. They are the standard tensions of any jurisdiction regulating a fast-moving technology, and European and American regulators are confronting versions of each. ## Where cooperation is actually happening The areas of genuine international convergence are less dramatic than the disagreements and more useful: - **Health AI governance**, where the WHO framing shift toward prevention and continuous health reflects shared problems in ageing societies. - **Neurotechnology ethics**, where every country faces identical questions about neural data and cognitive privacy and where UNESCO and national bodies have been working in parallel. - **Testing and evaluation methodology**, where shared benchmarks for model safety are in everyone's interest. At WAIC 2026 in Shanghai, 177 international procurement delegations attended and 351 products made their global debut. Whatever the governance disagreements, the commercial and technical conversation is not decoupling — it is intensifying. ## The honest summary China's approach is not "no rules" and it is not "open rules." It is early, dense, domestically calibrated rules, paired with active international standards engagement. The case for it is that it lets deployment proceed at scale with defined accountability. The case against is that density and specificity can harden into barriers. Both are true, and the balance will be determined less by the text of the regulations than by how they are revised — which, so far, they have been, repeatedly. *Sources: Xinhua reporting on the July 2026 Politburo meeting; CAC and MIIT regulatory releases; World Health Assembly 2026 coverage; WAIC 2026 organisers' data.* --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-governance-and-standards Free to quote with attribution and a link to the original.